Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study

Musha, Atsushi; Kubo, Nobuteru; Kawamura, Hidemasa; Okano, Naoko; Sato, Hiro; Okada, Ken-ichi; Osu, Naoto; Yumisaki, Hikaru; Adachi, Akiko; Takayasu, Yukihiro; Shino, Masato; Nikkuni, Osamu; Ida, Shota; Shirai, Katsuyuki; Saitoh, Jun‐ichi; Yokoo, Satoshi; Chikamatsu, Kazuaki; Ohno, Tatsuya

doi:10.21873/anticanres.15614

Cited by 9 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that LGMS shows a growth pattern that infiltrates the surrounding tissue, close attention must be paid in setting the area for irradiation. Since the tumor is surrounded by important tissues in head and neck lesions, the use of an intensity modulated technique to reduce irradiation to normal tissues and to reduce adverse events [ 31 ], and the use of carbon ion beams and proton beams to obtain good local control with fewer adverse events [ 32 , 33 , 34 ], may be necessary in these cases. In this study, distant metastases occurred in 4.2% of patients, which was comparable to previous reports (0–9.1%) [ 1 , 3 , 5 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Kito

Okamoto

et al. 2023

Cancers

View full text Add to dashboard Cite

This retrospective multicenter study aimed to analyze the clinical features and prognosis of 24 patients diagnosed with LGMS between 2002 and 2019 in the Japanese sarcoma network. Twenty-two cases were surgically treated and two cases were treated with radical radiotherapy (RT). The pathological margin was R0 in 14 cases, R1 in 7 cases, and R2 in 1 case. The best overall response in the two patients who underwent radical RT was one complete response and one partial response. Local relapse occurred in 20.8% of patients. Local relapse-free survival (LRFS) was 91.3% at 2 years and 75.4% at 5 years. In univariate analysis, tumors of 5 cm or more were significantly more likely to cause local relapse (p < 0.01). In terms of the treatment of relapsed tumors, surgery was performed in two cases and radical RT was performed in three cases. None of the patients experienced a second local relapse. Disease-specific survival was 100% at 5 years. A wide excision aimed at the microscopically R0 margin is considered the standard treatment for LGMS. However, RT may be a viable option in unresectable cases or in cases where surgery is expected to cause significant functional impairment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Kito

Okamoto

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Polystyrene (PS) has good transparency, lack of color, ease of manufacture, thermal stability, low specific gravity (1.04-1.12 g/cm 3 ) and relatively high modulus [25]. PS is resistant to impact strength and environmental stress cracking [26].…”

Section: Methodsmentioning

confidence: 99%

“…Heavy ion therapy currently stands as the prevailing approach in tumor treatment [1][2][3]. These ions exhibit a high linear energy transfer (LET) as they deposit a greater amount of energy (keV) per unit distance (µm) than photons at the Bragg peak [4].…”

Section: Introductionmentioning

confidence: 99%

Enhancing Tissue Equivalence in 7Li Heavy Ion Therapy with MC Algorithm Optimized Polymer-Based Bioinks

Ekinci,

Acici,

Asuroglu

2023

JFB

View full text Add to dashboard Cite

The unique physical properties of heavy ion beams, particularly their distinctive depth–dose distribution and sharp lateral dose reduction profiles, have led to their widespread adoption in tumor therapy worldwide. However, the physical properties of heavy ion beams must be investigated to deliver a sufficient dose to tumors without damaging organs at risk. These studies should be performed on phantoms made of biomaterials that closely mimic human tissue. Polymers can serve as soft tissue substitutes and are suitable materials for building radiological phantoms due to their physical, mechanical, biological, and chemical properties. Extensive research, development, and applications of polymeric biomaterials have been encouraged due to these properties. In this study, we investigated the ionization, recoils, phonon release, collision events, and lateral straggle properties of polymeric biomaterials that closely resemble soft tissue using lithium-ion beams and Monte Carlo Transport of Ions in Matter simulation. The results indicated that the Bragg peak position closest to soft tissue was achieved with a 7.3% difference in polymethylmethacrylate, with an average recoils value of 10.5%. Additionally, average values of 33% were observed in collision events and 22.6% in lateral straggle. A significant contribution of this study to the existing literature lies in the exploration of secondary interactions alongside the assessment of linear energy transfer induced by the 7Li beam used for treatment. Furthermore, we analyzed the tissue-equivalent properties of polymer biomaterials using heavy ion beams, taking into account phonon release resulting from ionization, recoils, lateral straggle, and all other interactions. This approach allows for the evaluation of the most suitable polymeric biomaterials for heavy ion therapy while considering the full range of interactions involved.

show abstract

“…Bone sarcomas comprise a group of rare cancers that include some of the few entities for which particle-based radiotherapy has emerged as standard indications and the treatment of choice (11,14,22), such as skull base, spinal and pelvic chondrosarcomas and chordomas (23)(24)(25)(26). Carbon ion treatment is shown to be effective for bone and soft tissue sarcomas of the head and neck with adverse events within the expected range (27). In addition, patients with axial osteosarcoma, Ewing sarcoma or other childhood sarcomas, such as rhabdo-myosarcoma (22), are increasingly being given proton therapy as the preferred local treatment modality.…”

mentioning

confidence: 99%

Exploring the Patient Perspective of Bone Sarcoma Survivors Who Have Undergone Particle Radiotherapy Abroad

et al. 2023

View full text Add to dashboard Cite

Background/Aim: Sarcoma patients' experiences of their health-related quality of life and late effects following particle therapy are sparse. Such knowledge is essential to optimize treatment compliance and follow-up care related to this rapidly developing, but still centralized treatment modality. Patients and Methods: This qualitative study has an explorative design and applies a phenomenological and hermeneutical approach based on semi-structured interviews with 12 bone sarcoma patients who had undergone particle therapy abroad. The data were interpreted using thematic analysis. Results: Several of the participants called for more information about how the treatment would be carried out, its acute side effects and late complications. Most participants had positive experiences from the treatment and their stay abroad, but several struggled with late effects and other challenges. Themes that emerged from the analysis were "importance of being prepared", "treatment and stay abroad", "basically healthy, but with health problems and challenges". Conclusion: Oncologists who inform and refer patients to particle therapy abroad must have sufficient experience of this treatment modality, prognoses, acute side effects, and late complications. Findings derived from this study may improve treatment preparation and compliance, enhance understanding of individual patient challenges to reduce stress and worry, and lead to better follow-up care and consequently quality of life of this selected group of bone sarcoma patients.Sarcoma survivors frequently struggle with late effects of treatment (1-4). The literature is sparse on their experiences, their health-related quality of life and late effects following particle therapy (5). Only one quantitative article on sarcoma patients was identified in which Srivastava et al. (6) studied chordoma and chondrosarcoma patients and concluded that their quality of life was not adversely affected during treatment, which allowed them to enjoy a normal life despite the lengthy treatment. No qualitative studies involving patients' own narratives have been found for these diagnostic groups of bone sarcomas. However, limited qualitative research has been published on the perspectives of patients treated with protons for brain cancer (7, 8), and relatives' perspectives on proton treatment given to pediatric cancer patients (9, 10). Living in a hotel, often alone, during treatment has been reported as an additional challenge by patients with primary brain tumors being treated with proton therapy far from home (8). Patients experienced an ongoing process in which they made several adjustments to cope, enhance their well-being, and manage the altered social context (8). Furthermore, concerns about diagnosis, treatment, and symptoms, in addition to spending time away from home, represent a significant additional burden for both patients and their family members (10).Particle-beam therapy is of increasing clinical use primarily due to its physical characteristics with improved dose distributions, an...

show abstract

Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study

Cited by 9 publications

References 24 publications

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Enhancing Tissue Equivalence in 7Li Heavy Ion Therapy with MC Algorithm Optimized Polymer-Based Bioinks

Exploring the Patient Perspective of Bone Sarcoma Survivors Who Have Undergone Particle Radiotherapy Abroad

Contact Info

Product

Resources

About